caption a7 parameter coculturing organism lower ci estimate upper ci statistical significance atcc s aureus  (ATCC)

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure

doi: 10.1128/AAC.02414-20

Figure Lengend Snippet: Summary PK/PD statistics a

Article Snippet: Each panel represents the bacterial species being observed. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Parameter Coculturing organism Lower CI Estimate Upper CI Statistical significance ATCC S. aureus vs meropenem E Δ None −5.85 −4.61 −3.38 E max −3.36 −4.03 −4.71 EC 50 2.14e−2 6.16e−2 1.02e−1 E Δ ATCC A. baumannii −4.97 −4.16 −3.35 E max −3.29 −3.73 −4.17 EC 50 −3.72e−4 9.40e−3 1.92e−2 E Δ CRAB −2.85 −2.23 −1.61 * E max 2.68 3.02 3.36 * EC 50 5.73e−2 9.99e−2 1.43e−1 CDC S. aureus vs meropenem E Δ None −5.01 −3.89 −2.77 E max −3.48 −4.09 −4.70 EC 50 3.23e−2 7.42e−2 1.16e−1 E Δ ATCC A. baumannii −4.55 −3.92 −3.28 E max 3.81 4.16 4.50 EC 50 1.93e−2 3.06e−2 4.19e−2 E Δ CRAB −6.91 −5.53 −4.14 E max −4.29 −5.04 −5.79 EC 50 3.35e−2 6.89e−2 1.04e−1 ATCC A. baumannii vs meropenem E Δ None −3.33 −2.88 −2.43 E max −2.61 −2.91 −3.21 EC 50 9.23e−1 1.74 2.56 E Δ ATCC S. aureus −3.73 −3.33 −2.94 E max −2.80 −3.03 −3.26 EC 50 3.79e−1 5.74e−1 7.70e−1 * E Δ CDC S. aureus −3.59 −2.95 −2.30 E max −2.79 −3.18 −3.57 EC 50 3.04e−1 6.69e−1 1.03 Open in a separate window a * indicates statistical significance compared to monoculture as indicated by nonoverlapping 95% confidence intervals.

Techniques:

Journal: ACS Medicinal Chemistry Letters

Article Title: Structure–Activity Relationship for the Oxadiazole Class of Antibacterials

doi: 10.1021/acsmedchemlett.9b00379

Figure Lengend Snippet: Pharmacokinetics of 72c after single iv and po administration at 20 mg/kg to mice (n = 3 mice per time point).

Article Snippet: Oxadiazole 72c showed better activity against MRSA strains NRS70, VRS1, and VRS2, and S. hemolyticus , B. cereus , B. licheniformis , and E. faecalis ATCC 29212 than oxadiazole 8 . table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Organism 72c 8 vancomycin linezolid S. aureus ATCC 29213 b 1–2 4 1 2 S. aureus ATCC 27660 c 2–4 4 2 1 S. aureus N315 (NRS70) c 1 2 1 1 S. aureus NRS100 (COL) c 2 2 2 1 S. aureus NRS119 d 1–2 2 1 32 S. aureus NRS120 d 2 2 1 32 S. aureus VRS1 e 1 2 64 1 S. aureus VRS2 f 1 2 32 1 S. epidermidis ATCC 35547 1 2 4 0.5 S. hemolyticus ATCC 29970 2 4–8 4 1 B. cereus ATCC 13061 4 16 1 0.5 B. licheniformis ATCC 12759 2 8 0.5 0.5 E. faecalis ATCC 29212 b 4 8 2 1 E. faecalis 201 (Van S) g 4 4 1 1 E. faecalis 99 (Van R) h 4 4 128 1 E. faecium 119–39A (Van S) g 1 1 0.5 1 E. faecium 106 (Van R) h 1 2 128 1 E. faecium NCTC 7171 1 2 0.5 1 Open in a separate window a MIC in μg/mL. b A quality-control strain to monitor accuracy of MIC testing. c mecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid. d mecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid. e Vancomycin-resistant MRSA ( vanA ) clinical isolate from Michigan. f Vancomycin-resistant MRSA ( vanA ) clinical isolate from Pennsylvania. g Vancomycin-susceptible clinical isolate. h Vancomycin-resistant clinical isolate. caption a8 Activity of Oxadiazoles against Gram-Positive Organisms a A PK study was conducted with 72c after intravenous (iv) and oral (po) administration ( ).

Techniques: Drug discovery

Journal: ACS Medicinal Chemistry Letters

Article Title: Structure–Activity Relationship for the Oxadiazole Class of Antibacterials

doi: 10.1021/acsmedchemlett.9b00379

Figure Lengend Snippet: Efficacy of 72c in a mouse neutropenic thigh MRSA infection model using (a) NRS70 (linezolid-sensitive) and (b) NRS119 (linezolid-resistant). Mice (n = 8 per group) were made neutropenic by administration of cyclophosphamide. Bacteria (105 cfu) were injected intramuscularly into the right thigh. A single 40 mg/kg oral dose of vehicle, 72c, 8, or linezolid was given 1 h after infection. The thighs were harvested 48 h after infection, homogenized, and plated for colony counts. Mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 by Mann–Whitney U test two-paired.

Article Snippet: Oxadiazole 72c showed better activity against MRSA strains NRS70, VRS1, and VRS2, and S. hemolyticus , B. cereus , B. licheniformis , and E. faecalis ATCC 29212 than oxadiazole 8 . table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Organism 72c 8 vancomycin linezolid S. aureus ATCC 29213 b 1–2 4 1 2 S. aureus ATCC 27660 c 2–4 4 2 1 S. aureus N315 (NRS70) c 1 2 1 1 S. aureus NRS100 (COL) c 2 2 2 1 S. aureus NRS119 d 1–2 2 1 32 S. aureus NRS120 d 2 2 1 32 S. aureus VRS1 e 1 2 64 1 S. aureus VRS2 f 1 2 32 1 S. epidermidis ATCC 35547 1 2 4 0.5 S. hemolyticus ATCC 29970 2 4–8 4 1 B. cereus ATCC 13061 4 16 1 0.5 B. licheniformis ATCC 12759 2 8 0.5 0.5 E. faecalis ATCC 29212 b 4 8 2 1 E. faecalis 201 (Van S) g 4 4 1 1 E. faecalis 99 (Van R) h 4 4 128 1 E. faecium 119–39A (Van S) g 1 1 0.5 1 E. faecium 106 (Van R) h 1 2 128 1 E. faecium NCTC 7171 1 2 0.5 1 Open in a separate window a MIC in μg/mL. b A quality-control strain to monitor accuracy of MIC testing. c mecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid. d mecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid. e Vancomycin-resistant MRSA ( vanA ) clinical isolate from Michigan. f Vancomycin-resistant MRSA ( vanA ) clinical isolate from Pennsylvania. g Vancomycin-susceptible clinical isolate. h Vancomycin-resistant clinical isolate. caption a8 Activity of Oxadiazoles against Gram-Positive Organisms a A PK study was conducted with 72c after intravenous (iv) and oral (po) administration ( ).

Techniques: Infection, Bacteria, Injection, MANN-WHITNEY

Journal: ACS Medicinal Chemistry Letters

Article Title: Structure–Activity Relationship for the Oxadiazole Class of Antibacterials

doi: 10.1021/acsmedchemlett.9b00379

Figure Lengend Snippet: In Vitro Evaluation of Oxadiazoles

Article Snippet: Oxadiazole 72c showed better activity against MRSA strains NRS70, VRS1, and VRS2, and S. hemolyticus , B. cereus , B. licheniformis , and E. faecalis ATCC 29212 than oxadiazole 8 . table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Organism 72c 8 vancomycin linezolid S. aureus ATCC 29213 b 1–2 4 1 2 S. aureus ATCC 27660 c 2–4 4 2 1 S. aureus N315 (NRS70) c 1 2 1 1 S. aureus NRS100 (COL) c 2 2 2 1 S. aureus NRS119 d 1–2 2 1 32 S. aureus NRS120 d 2 2 1 32 S. aureus VRS1 e 1 2 64 1 S. aureus VRS2 f 1 2 32 1 S. epidermidis ATCC 35547 1 2 4 0.5 S. hemolyticus ATCC 29970 2 4–8 4 1 B. cereus ATCC 13061 4 16 1 0.5 B. licheniformis ATCC 12759 2 8 0.5 0.5 E. faecalis ATCC 29212 b 4 8 2 1 E. faecalis 201 (Van S) g 4 4 1 1 E. faecalis 99 (Van R) h 4 4 128 1 E. faecium 119–39A (Van S) g 1 1 0.5 1 E. faecium 106 (Van R) h 1 2 128 1 E. faecium NCTC 7171 1 2 0.5 1 Open in a separate window a MIC in μg/mL. b A quality-control strain to monitor accuracy of MIC testing. c mecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid. d mecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid. e Vancomycin-resistant MRSA ( vanA ) clinical isolate from Michigan. f Vancomycin-resistant MRSA ( vanA ) clinical isolate from Pennsylvania. g Vancomycin-susceptible clinical isolate. h Vancomycin-resistant clinical isolate. caption a8 Activity of Oxadiazoles against Gram-Positive Organisms a A PK study was conducted with 72c after intravenous (iv) and oral (po) administration ( ).

Techniques: In Vitro, Clinical Proteomics, Protein Binding

Journal: ACS Medicinal Chemistry Letters

Article Title: Structure–Activity Relationship for the Oxadiazole Class of Antibacterials

doi: 10.1021/acsmedchemlett.9b00379

Figure Lengend Snippet: Activity of Oxadiazoles against Gram-Positive Organisms a

Article Snippet: Oxadiazole 72c showed better activity against MRSA strains NRS70, VRS1, and VRS2, and S. hemolyticus , B. cereus , B. licheniformis , and E. faecalis ATCC 29212 than oxadiazole 8 . table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Organism 72c 8 vancomycin linezolid S. aureus ATCC 29213 b 1–2 4 1 2 S. aureus ATCC 27660 c 2–4 4 2 1 S. aureus N315 (NRS70) c 1 2 1 1 S. aureus NRS100 (COL) c 2 2 2 1 S. aureus NRS119 d 1–2 2 1 32 S. aureus NRS120 d 2 2 1 32 S. aureus VRS1 e 1 2 64 1 S. aureus VRS2 f 1 2 32 1 S. epidermidis ATCC 35547 1 2 4 0.5 S. hemolyticus ATCC 29970 2 4–8 4 1 B. cereus ATCC 13061 4 16 1 0.5 B. licheniformis ATCC 12759 2 8 0.5 0.5 E. faecalis ATCC 29212 b 4 8 2 1 E. faecalis 201 (Van S) g 4 4 1 1 E. faecalis 99 (Van R) h 4 4 128 1 E. faecium 119–39A (Van S) g 1 1 0.5 1 E. faecium 106 (Van R) h 1 2 128 1 E. faecium NCTC 7171 1 2 0.5 1 Open in a separate window a MIC in μg/mL. b A quality-control strain to monitor accuracy of MIC testing. c mecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid. d mecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid. e Vancomycin-resistant MRSA ( vanA ) clinical isolate from Michigan. f Vancomycin-resistant MRSA ( vanA ) clinical isolate from Pennsylvania. g Vancomycin-susceptible clinical isolate. h Vancomycin-resistant clinical isolate. caption a8 Activity of Oxadiazoles against Gram-Positive Organisms a A PK study was conducted with 72c after intravenous (iv) and oral (po) administration ( ).

Techniques: Activity Assay

Journal: ACS Medicinal Chemistry Letters

Article Title: Structure–Activity Relationship for the Oxadiazole Class of Antibacterials

doi: 10.1021/acsmedchemlett.9b00379

Figure Lengend Snippet: Pharmacokinetic Parameters of 72c in Mice

Article Snippet: Oxadiazole 72c showed better activity against MRSA strains NRS70, VRS1, and VRS2, and S. hemolyticus , B. cereus , B. licheniformis , and E. faecalis ATCC 29212 than oxadiazole 8 . table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Organism 72c 8 vancomycin linezolid S. aureus ATCC 29213 b 1–2 4 1 2 S. aureus ATCC 27660 c 2–4 4 2 1 S. aureus N315 (NRS70) c 1 2 1 1 S. aureus NRS100 (COL) c 2 2 2 1 S. aureus NRS119 d 1–2 2 1 32 S. aureus NRS120 d 2 2 1 32 S. aureus VRS1 e 1 2 64 1 S. aureus VRS2 f 1 2 32 1 S. epidermidis ATCC 35547 1 2 4 0.5 S. hemolyticus ATCC 29970 2 4–8 4 1 B. cereus ATCC 13061 4 16 1 0.5 B. licheniformis ATCC 12759 2 8 0.5 0.5 E. faecalis ATCC 29212 b 4 8 2 1 E. faecalis 201 (Van S) g 4 4 1 1 E. faecalis 99 (Van R) h 4 4 128 1 E. faecium 119–39A (Van S) g 1 1 0.5 1 E. faecium 106 (Van R) h 1 2 128 1 E. faecium NCTC 7171 1 2 0.5 1 Open in a separate window a MIC in μg/mL. b A quality-control strain to monitor accuracy of MIC testing. c mecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid. d mecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid. e Vancomycin-resistant MRSA ( vanA ) clinical isolate from Michigan. f Vancomycin-resistant MRSA ( vanA ) clinical isolate from Pennsylvania. g Vancomycin-susceptible clinical isolate. h Vancomycin-resistant clinical isolate. caption a8 Activity of Oxadiazoles against Gram-Positive Organisms a A PK study was conducted with 72c after intravenous (iv) and oral (po) administration ( ).

Techniques:

Journal: Protein Science : A Publication of the Protein Society

Article Title: Structures of glyceraldehyde 3‐phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatis

doi: 10.1002/pro.3824

Figure Lengend Snippet: Macromolecule production information

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 Table 3 caption a7 Source organism Neisseria gonorrhoeae Chlamydia trachomatis DNA source ATCC® 700825D‐5TM gDNA, strain D/UW‐3‐Cx Forward primer 5′ CTCACCACCACCACCACCATATG AGCATCAAAGTAGCGATTAACG‐3’ 5′ CTCACCACCACCACCACCATATG AG AATTGTGATTAATGGTTTTGG‐3′ Reverse primer 5′ ATCCTATCTTACTCACTTAG ATTTTGCCTGCGAAGTATTCCAA‐3′ 5′ ATCCTATCTTACTCACTTATTTAG AG TTTTCTTGTACGTACTCTA‐3′ Cloning vector pBG1861 pBG1861 Expression vector pBG1861 pBG1861 Complete amino acid sequence of the construct produced MSIKVAINGFGRIGRLALRQIEKAHGIEVAAVNDLTPAEMLLHLFKYDSTQGRFQGTELKDDAIVVNGREIKVFANPNPEELPWGELGVDVVLECTGFFTNKTKAEAHIRAGARKVVISAPGGNDVKTVVYGVNQDILDGSETVISAASCTTNCLAPMAAVLQKEFGVVEGLMTTIHAYTGDQNTLDAPHRKGDLRRARAAALNIVPNSGAAKAIGLVIPELNGKLDGSAQRVPVATGSLTELVSVLERPATKEEINAAMKAASSESYGYNEDQIVSSDVVGIEYGSLFDATQTRVMTVGGKQLVKTVAWYDNEMSYTCQLVRTLEYFAGKI MRIVINGFGR IGRLVLRQILKRNSPIEVV AINDLVAGDLLTYLFKYDSTHGSFAPQA TFSDGCLVMGERKVHFLAEKDVQKLPW KDLDVDVVVESTGLFVNRDDVAKHLDS GAKRVLITAPAKGDVPTFVMGVNHQQF DPADVIISNASCTTNCLAPLAKVLLDNF GIEEGLMTTVHAATATQSVVDGPSRKD WRGGRGAFQNIIPASTGAAKAVGLCLP ELKGKLTGMAFRVPVADVSVVDLTVKL SSATTYEAICEAVKHAANTSMKNIMYY TEEAVVSSDFIGCEYSSVFDAQAGVALN DRFFKLVAWYDNEIGYATRIVDLLEYV QENSK Open in a separate window Macromolecule production information The proteins were purified by a two‐step protocol involving immobilized metal affinity chromatography (IMAC) and size‐exclusion chromatography (SEC).

Techniques: Cloning, Plasmid Preparation, Expressing, Sequencing, Construct, Produced

Journal: Protein Science : A Publication of the Protein Society

Article Title: Structures of glyceraldehyde 3‐phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatis

doi: 10.1002/pro.3824

Figure Lengend Snippet: Crystallization

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 Table 3 caption a7 Source organism Neisseria gonorrhoeae Chlamydia trachomatis DNA source ATCC® 700825D‐5TM gDNA, strain D/UW‐3‐Cx Forward primer 5′ CTCACCACCACCACCACCATATG AGCATCAAAGTAGCGATTAACG‐3’ 5′ CTCACCACCACCACCACCATATG AG AATTGTGATTAATGGTTTTGG‐3′ Reverse primer 5′ ATCCTATCTTACTCACTTAG ATTTTGCCTGCGAAGTATTCCAA‐3′ 5′ ATCCTATCTTACTCACTTATTTAG AG TTTTCTTGTACGTACTCTA‐3′ Cloning vector pBG1861 pBG1861 Expression vector pBG1861 pBG1861 Complete amino acid sequence of the construct produced MSIKVAINGFGRIGRLALRQIEKAHGIEVAAVNDLTPAEMLLHLFKYDSTQGRFQGTELKDDAIVVNGREIKVFANPNPEELPWGELGVDVVLECTGFFTNKTKAEAHIRAGARKVVISAPGGNDVKTVVYGVNQDILDGSETVISAASCTTNCLAPMAAVLQKEFGVVEGLMTTIHAYTGDQNTLDAPHRKGDLRRARAAALNIVPNSGAAKAIGLVIPELNGKLDGSAQRVPVATGSLTELVSVLERPATKEEINAAMKAASSESYGYNEDQIVSSDVVGIEYGSLFDATQTRVMTVGGKQLVKTVAWYDNEMSYTCQLVRTLEYFAGKI MRIVINGFGR IGRLVLRQILKRNSPIEVV AINDLVAGDLLTYLFKYDSTHGSFAPQA TFSDGCLVMGERKVHFLAEKDVQKLPW KDLDVDVVVESTGLFVNRDDVAKHLDS GAKRVLITAPAKGDVPTFVMGVNHQQF DPADVIISNASCTTNCLAPLAKVLLDNF GIEEGLMTTVHAATATQSVVDGPSRKD WRGGRGAFQNIIPASTGAAKAVGLCLP ELKGKLTGMAFRVPVADVSVVDLTVKL SSATTYEAICEAVKHAANTSMKNIMYY TEEAVVSSDFIGCEYSSVFDAQAGVALN DRFFKLVAWYDNEIGYATRIVDLLEYV QENSK Open in a separate window Macromolecule production information The proteins were purified by a two‐step protocol involving immobilized metal affinity chromatography (IMAC) and size‐exclusion chromatography (SEC).

Techniques: Diffusion-based Assay, Protein Concentration

Journal: Protein Science : A Publication of the Protein Society

Article Title: Structures of glyceraldehyde 3‐phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatis

doi: 10.1002/pro.3824

Figure Lengend Snippet: Data collection and processing

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 Table 3 caption a7 Source organism Neisseria gonorrhoeae Chlamydia trachomatis DNA source ATCC® 700825D‐5TM gDNA, strain D/UW‐3‐Cx Forward primer 5′ CTCACCACCACCACCACCATATG AGCATCAAAGTAGCGATTAACG‐3’ 5′ CTCACCACCACCACCACCATATG AG AATTGTGATTAATGGTTTTGG‐3′ Reverse primer 5′ ATCCTATCTTACTCACTTAG ATTTTGCCTGCGAAGTATTCCAA‐3′ 5′ ATCCTATCTTACTCACTTATTTAG AG TTTTCTTGTACGTACTCTA‐3′ Cloning vector pBG1861 pBG1861 Expression vector pBG1861 pBG1861 Complete amino acid sequence of the construct produced MSIKVAINGFGRIGRLALRQIEKAHGIEVAAVNDLTPAEMLLHLFKYDSTQGRFQGTELKDDAIVVNGREIKVFANPNPEELPWGELGVDVVLECTGFFTNKTKAEAHIRAGARKVVISAPGGNDVKTVVYGVNQDILDGSETVISAASCTTNCLAPMAAVLQKEFGVVEGLMTTIHAYTGDQNTLDAPHRKGDLRRARAAALNIVPNSGAAKAIGLVIPELNGKLDGSAQRVPVATGSLTELVSVLERPATKEEINAAMKAASSESYGYNEDQIVSSDVVGIEYGSLFDATQTRVMTVGGKQLVKTVAWYDNEMSYTCQLVRTLEYFAGKI MRIVINGFGR IGRLVLRQILKRNSPIEVV AINDLVAGDLLTYLFKYDSTHGSFAPQA TFSDGCLVMGERKVHFLAEKDVQKLPW KDLDVDVVVESTGLFVNRDDVAKHLDS GAKRVLITAPAKGDVPTFVMGVNHQQF DPADVIISNASCTTNCLAPLAKVLLDNF GIEEGLMTTVHAATATQSVVDGPSRKD WRGGRGAFQNIIPASTGAAKAVGLCLP ELKGKLTGMAFRVPVADVSVVDLTVKL SSATTYEAICEAVKHAANTSMKNIMYY TEEAVVSSDFIGCEYSSVFDAQAGVALN DRFFKLVAWYDNEIGYATRIVDLLEYV QENSK Open in a separate window Macromolecule production information The proteins were purified by a two‐step protocol involving immobilized metal affinity chromatography (IMAC) and size‐exclusion chromatography (SEC).

Techniques:

Journal: Protein Science : A Publication of the Protein Society

Article Title: Structures of glyceraldehyde 3‐phosphate dehydrogenase in Neisseria gonorrhoeae and Chlamydia trachomatis

doi: 10.1002/pro.3824

Figure Lengend Snippet: Structure solution and refinement

Article Snippet: 33 table ft1 table-wrap mode="anchored" t5 Table 3 caption a7 Source organism Neisseria gonorrhoeae Chlamydia trachomatis DNA source ATCC® 700825D‐5TM gDNA, strain D/UW‐3‐Cx Forward primer 5′ CTCACCACCACCACCACCATATG AGCATCAAAGTAGCGATTAACG‐3’ 5′ CTCACCACCACCACCACCATATG AG AATTGTGATTAATGGTTTTGG‐3′ Reverse primer 5′ ATCCTATCTTACTCACTTAG ATTTTGCCTGCGAAGTATTCCAA‐3′ 5′ ATCCTATCTTACTCACTTATTTAG AG TTTTCTTGTACGTACTCTA‐3′ Cloning vector pBG1861 pBG1861 Expression vector pBG1861 pBG1861 Complete amino acid sequence of the construct produced MSIKVAINGFGRIGRLALRQIEKAHGIEVAAVNDLTPAEMLLHLFKYDSTQGRFQGTELKDDAIVVNGREIKVFANPNPEELPWGELGVDVVLECTGFFTNKTKAEAHIRAGARKVVISAPGGNDVKTVVYGVNQDILDGSETVISAASCTTNCLAPMAAVLQKEFGVVEGLMTTIHAYTGDQNTLDAPHRKGDLRRARAAALNIVPNSGAAKAIGLVIPELNGKLDGSAQRVPVATGSLTELVSVLERPATKEEINAAMKAASSESYGYNEDQIVSSDVVGIEYGSLFDATQTRVMTVGGKQLVKTVAWYDNEMSYTCQLVRTLEYFAGKI MRIVINGFGR IGRLVLRQILKRNSPIEVV AINDLVAGDLLTYLFKYDSTHGSFAPQA TFSDGCLVMGERKVHFLAEKDVQKLPW KDLDVDVVVESTGLFVNRDDVAKHLDS GAKRVLITAPAKGDVPTFVMGVNHQQF DPADVIISNASCTTNCLAPLAKVLLDNF GIEEGLMTTVHAATATQSVVDGPSRKD WRGGRGAFQNIIPASTGAAKAVGLCLP ELKGKLTGMAFRVPVADVSVVDLTVKL SSATTYEAICEAVKHAANTSMKNIMYY TEEAVVSSDFIGCEYSSVFDAQAGVALN DRFFKLVAWYDNEIGYATRIVDLLEYV QENSK Open in a separate window Macromolecule production information The proteins were purified by a two‐step protocol involving immobilized metal affinity chromatography (IMAC) and size‐exclusion chromatography (SEC).

Techniques: